Latest research on Meropenem

Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.

Latest findings

One meta-review by Jamal et al. examined the effect of RRT settings on Meropenem, Piperacillin and Vancomycin CL. [source, 2016]
The authors found that the setting most correlated with Antibiotic CL was effluent flow rate for Meropenem (Spearman correlation coefficient (rs) = 0.43; p = 0.12), Piperacillin (rs = 0.77; p = 0.10), and Vancomycin (rs = 0.90; p = 0.08). [source, 2016]
We aim to develop an individualised optimal dosing algorithm that accounts for the relevant effects of RRT modalities and patient clinical characteristics on dosing requirements for Vancomycin, Linezolid, piperacillin-tazobactam and Meropenem. [source, 2016]
This is a multi-national observational PK study designed to analyse PK data using a population PK approach to identify covariates associated with changes in PK parameters for five commonly prescribed antibiotics, Vancomycin, Linezolid, piperacillin/tazobactam and Meropenem in critically ill patients with AKI who are undergoing RRT. [source, 2016]
Prevalence of resistance to different antibiotics among the isolates was; Cefazolin (65.78%), Cefoxitin (73.68%), Cefoperazone (34.21%), Cefepime (68.42%), gentamycin (94.73%), Amikacin (50%), Kanamycin (92.10%), STREPTOMYCIN (65.78%), spectinomycin (73.52%), piperacillin/tazobactam (26.31%), Ampicillin (89%), Clindamycin (34.21%), TETRACYCLINE (60.52%), Meropenem (76.31%), trimethoprime (63.15%), and co-trimoxazole (76.31%). [source, 2016]
The number of eligible patients to be enrolled for any individual Antibiotic is 150 for patients receiving Vancomycin, piperacillin-tazobactam, or Meropenem. [source, 2016]
For Vancomycin, piperacillin/tazobactam and Meropenem, to construct a 95 % confidence boundary of clearance, with standard deviation as high as 2.5 L/h with 80 % power, we will need 45 samples of patient data for each particular RRT modality. [source, 2016]
This comprehensive data set will permit the description of detailed PK data, and allow further analysis of the effect of critical illness, AKI and RRT on the drug disposition of five of the most commonly used antibiotics in ICU patients, namely, Vancomycin, Linezolid, piperacillin/tazobactam and Meropenem. [source, 2016]
Thus, diagnosis of urosepsis with DIC was most likely and Antibiotic treatment was broadened to Meropenem and Vancomycin to include common resistant bacteria. [source, 2016]
Eighteen antibiotics belonging to nine different classes i.e., (a) cephalosporins: Cefazolin 30 μg (1st generation), Cefoxitin 30 μg (2nd generation), Cefoperazone 75 μg (3rd generation) and Cefepime 30 μg (4th generation), (b) aminoglycosides: Gentamicin 10 μg, Amikacin 30 μg, Kanamycin 30 μg, STREPTOMYCIN 20 μg, and spectinomycin 100 μg, (c) penicillins: Methicillin 30 μg, piperacillin/tazobactam 100/10 μg, and Ampicillin 10 μg, (d) lincosamide: Clindamycin 2 μg, (e) tetracycline: tetracycline 30 μg, (f) carbapenem: Meropenem 10 μg, (g) dihydrofolate reductase inhibitor: Trimethoprim 20 μg, and (h) folate pathway inhibitor: co-trimoxazole 25 μg, (i) glycopeptide: Vancomycin 30 μg were selected according to published recommendations and their widespread use in the treatment of various diseases (Gadepalli et al., 2006). [source, 2016]